REZOLUTE, INC. Form DEF 14C: Definitive information statement
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2014-04-10: Form DEF 14C; Period of report 2014-04-09; Description Definitive information statement; Document antriabio_def14c-041014.htm.
- 2012-12-19: Form DEF 14C; Period of report 2012-12-19; Description Definitive information statement; Document fitsmystyle-def14c_121912.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2014-04-10 | DEF 14C | 2014-04-09 | Definitive information statement | antriabio_def14c-041014.htm |
| 2012-12-19 | DEF 14C | 2012-12-19 | Definitive information statement | fitsmystyle-def14c_121912.htm |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |